These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

482 related items for PubMed ID: 18028479

  • 21. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J.
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [Abstract] [Full Text] [Related]

  • 22. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL, Marton E, Plander M.
    Orv Hetil; 2011 Nov 06; 152(45):1795-803. PubMed ID: 22011365
    [Abstract] [Full Text] [Related]

  • 23. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G, Cerny-Reiterer S, Herrmann H, Blatt K, Bilban M, Gisslinger H, Gisslinger B, Müllauer L, Kralovics R, Mannhalter C, Valent P, Mayerhofer M.
    FASEB J; 2012 Feb 06; 26(2):894-906. PubMed ID: 22051730
    [Abstract] [Full Text] [Related]

  • 24. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
    Hussein K, Bock O, Kreipe H.
    Pathobiology; 2007 Feb 06; 74(2):72-80. PubMed ID: 17587878
    [Abstract] [Full Text] [Related]

  • 25. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Barbui T, Thiele J, Vannucchi AM, Tefferi A.
    Blood Cancer J; 2015 Aug 14; 5(8):e337. PubMed ID: 26832847
    [Abstract] [Full Text] [Related]

  • 26. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN, Dekanić A, Hadzisejdić I, Kusen I, Matusan-Ilijas K, Grohovac D, Grahovac B, Jonjić N.
    Coll Antropol; 2012 Sep 14; 36(3):859-65. PubMed ID: 23213945
    [Abstract] [Full Text] [Related]

  • 27. [The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].
    Gong XB, Zhang XH, Lu XG, Tang QS, Gao X, Yang J.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jan 14; 33(1):25-30. PubMed ID: 22575188
    [Abstract] [Full Text] [Related]

  • 28. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
    Ha JS, Kim YK, Jung SI, Jung HR, Chung IS.
    Ann Lab Med; 2012 Nov 14; 32(6):385-91. PubMed ID: 23130336
    [Abstract] [Full Text] [Related]

  • 29. Dkk3 levels in patients with myeloproliferative neoplasms.
    Medinger M, Muesser P, Girsberger S, Skoda R, Tzankov A, Buser A, Passweg J, Tsakiris DΑ.
    Thromb Res; 2014 Feb 14; 133(2):218-21. PubMed ID: 24309205
    [Abstract] [Full Text] [Related]

  • 30. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.
    Ruella M, Salmoiraghi S, Risso A, Carobbio A, Buttiglieri S, Spatola T, Sivera P, Ricca I, Barbui T, Tarella C, Rambaldi A.
    Exp Hematol; 2013 Jul 14; 41(7):627-34. PubMed ID: 23542632
    [Abstract] [Full Text] [Related]

  • 31. Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis.
    Sangle N, Cook J, Perkins S, Teman CJ, Bahler D, Hickman K, Wilson A, Prchal J, Salama ME.
    Appl Immunohistochem Mol Morphol; 2014 Oct 14; 22(9):663-8. PubMed ID: 24897074
    [Abstract] [Full Text] [Related]

  • 32. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY, Fan Z, Zhang R, Shen YM, Chen W, Fei HR, Zhu ZL, Feng YF, Chen ZX, Xue YQ.
    Zhonghua Zhong Liu Za Zhi; 2009 Jul 14; 31(7):510-4. PubMed ID: 19950698
    [Abstract] [Full Text] [Related]

  • 33. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N.
    Br J Haematol; 2007 Mar 14; 136(5):745-51. PubMed ID: 17313377
    [Abstract] [Full Text] [Related]

  • 34. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
    Deadmond MA, Smith-Gagen JA.
    J Cancer Res Clin Oncol; 2015 Dec 14; 141(12):2131-8. PubMed ID: 25968903
    [Abstract] [Full Text] [Related]

  • 35. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
    Malak S, Labopin M, Saint-Martin C, Bellanne-Chantelot C, Najman A, French Group of Familial Myeloproliferative Disorders.
    Blood Cells Mol Dis; 2015 Dec 14; 49(3-4):170-6. PubMed ID: 22818858
    [Abstract] [Full Text] [Related]

  • 36. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
    Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A.
    Leukemia; 2008 Jul 14; 22(7):1299-307. PubMed ID: 18496562
    [Abstract] [Full Text] [Related]

  • 37. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera.
    Abdulkarim K, Ridell B, Johansson P, Kutti J, Safai-Kutti S, Andréasson B.
    Eur J Haematol; 2011 Feb 14; 86(2):148-55. PubMed ID: 21059102
    [Abstract] [Full Text] [Related]

  • 38. VEGF expression correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Gianelli U, Vener C, Raviele PR, Savi F, Somalvico F, Calori R, Iurlo A, Radaelli F, Fermo E, Bucciarelli P, Bori S, Coggi G, Deliliers GL.
    Am J Clin Pathol; 2007 Dec 14; 128(6):966-73. PubMed ID: 18024322
    [Abstract] [Full Text] [Related]

  • 39. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A.
    Semin Hematol; 1999 Jan 14; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [Abstract] [Full Text] [Related]

  • 40. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
    Payzin KB, Savasoglu K, Alacacioglu I, Ozdemirkiran F, Mutlu BB, Bener S, Calli AO, Kucukzeybek BB, Aksun S.
    Clin Lymphoma Myeloma Leuk; 2014 Dec 14; 14(6):525-33. PubMed ID: 24811089
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.